Corpus overview


Overview

MeSH Disease

Human Phenotype

Edema (2)

Weight loss (1)


Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    An Effective Inhaler Medication In The Treatment Of COVID-19 Associated Pneumonia 

    Authors: Oguz Guvenmez; Huseyin Keskin; Suayip Birinci; Semra Sardaş; Mehmet Salih Sevdi; Kanat Tayfun; Adnan Kazım Usalan; Mujgan Çalışkan; Mehmet Karabay; Burak Ay; Resat Duman; Nilay Duman; Asım Kayıklık; Mehmet Cubuk; Muhammed Furkan Kanca; Ayten Altıntaş; Ahmet Yaser Muslumanoglu

    doi:10.21203/rs.3.rs-53215/v2 Date: 2020-08-04 Source: ResearchSquare

    BackgroundCurrent COVID-19 treatment methods are in the form of oral tablets or intravenous therapy. However, even if the efficacy of these agents is shown in in-vitro studies, the same effect cannot be seen in in-vivo. This is because these treatments are intended to reach the lungs through the blood SERO. However, severe i nterstitial edema MESHD edema HP and blood SERO lood alveolar MESHDbarrier does not allow medications to reach the lungs effectively.ObjectiveIn the new inhaler treatment (N IT) MESHD given in this clinical study, the molecules that have antiviral, antioxidant and anti-inflammatory effects without any t oxicity MESHDwere brought together. This study aims to prevent rapid and effective clinical improvement in COVID-19 patients and prevent any complications related to COVID-19 i nfection. MESHDMethodsThis study approved by The Ministry of Health of Turkey. This clinical study was designed as a multi-center study and performed in Istanbul and Mersin, Turkey. The patients were divided into two groups. Patients were randomly assigned following simple randomization procedures. Eighty patients received the normal treatment protocol, while eighty patients received the new inhalation treatment protocol in addition to the normal treatment protocol. It was applied by connecting the T nebulizer device in intubated patients and with a nebulizer mask in non-intubated patients. Pulse oxygen saturation, respiratory rate, percentage of lung involvement, arterial blood SERO gas, and duration of hospitalization were compared after the treatment.ResultsOne of the most important points of this study is the duration of hospital stay between the two groups. The mean duration of hospitalization in group 1 was 6.5 ± 1.8; in group 2 it was 17.1 ± 2.4. The duration of stay in Group 1 was significantly lower than group 2. (P < 0.05) FOS (Finger oxygen saturation) values were 89.2 ± 4.8 and 96.1 ± 4.7 in group 1 at the end of the 3rd and 7th days, respectively. In group 2, it was 80.3 ± 5.9 and 84.6 ± 4.4. After treatment FOS levels were significantly higher in group 1 for days 3 and 7. (P < 0.05)ConclusionMethods of treatment with multiple molecules should be developed for complex diseases, not single molecule therapy. In this sense, this study is very important as it will bring a new perspective to the scientific world. With the treatment mentioned in the current study; It is important in terms of making a new prophylaxis and therapeutic plan for Covid-19. It is thought that it will be unique in terms of creating a treatment plan with low potential for natural and non-synthetic side effects instead of using toxic and side effects products.

    Age TRANS-dependent progression of SARS-CoV-2 infection MESHD in Syrian hamsters

    Authors: Nikolaus Osterrieder; Luca D. Bertzbach; Kristina Dietert; Azza Abdelgawad; Daria Vladimirova; Dusan Kunec; Donata Hoffmann; Martin Beer; Achim D. Gruber; Jakob Trimpert

    doi:10.1101/2020.06.10.144188 Date: 2020-06-10 Source: bioRxiv

    In late 2019, an outbreak of a severe respiratory disease MESHD caused by an emerging coronavirus, SARS-CoV-2, resulted in high morbidity and mortality in infected humans1. Complete understanding of COVID-19, the multi-faceted disease caused by SARS-CoV-2, requires suitable small animal models, as does the development and evaluation of vaccines and antivirals2. Because age TRANS-dependent differences of COVID-19 were identified in humans3, we compared the course of SARS-CoV-2 infection MESHD in young and aged TRANS Syrian hamsters. We show that virus replication in the upper and lower respiratory tract was independent of the age TRANS of the animals. However, older hamsters exhibited more pronounced and consistent weight loss HP weight loss MESHD. In situ hybridization in the lungs identified viral RNA in bronchial epithelium, alveolar epithelial MESHD cells type I and II, and macrophages. Histopathology revealed clear age TRANS-dependent differences, with young hamsters launching earlier and stronger immune cell influx than aged TRANS hamsters. The latter developed conspicuous alveolar MESHD and perivascular edema HP edema MESHD, indicating vascular leakage. In contrast, we observed rapid lung recovery at day 14 after infection MESHD only in young hamsters. We propose that comparative assessment in young versus aged TRANS hamsters of SARS-CoV-2 vaccines and treatments may yield valuable information as this small-animal model appears to mirror age TRANS-dependent differences in human patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.